

ImaBiotech Introduces Novel Panel to Its Imaging Mass Cytometry Services

LILLE, France - April 4, 2022 - [PRLog](#) -- ImaBiotech unveils today its "Immune Signature Panel" as part of its Imaging Mass Cytometry Services. The new panel will be presented in exclusivity at the #AACR22 meeting in New Orleans where ImaBiotech is holding the booth #825 in the exhibit hall.

ImaBiotech pioneered Imaging Mass Cytometry (IMC) applications for Biopharma launching its service in 2020. As a leading-edge technology, IMC enables highly multiplexed immunohistochemistry (mIHC) with simultaneous detection of up to 40 protein markers in the same tissue section with subcellular, single cell resolution.

Immune protection by cancer cells is mediated by the action of multiple immune-regulatory cell types, and the IMC technology allows to identify the key informative spatial information to more accurately profile those cells and understand their behavior. Combined with mass spectrometry imaging (MSI) developed by ImaBiotech, these molecular techniques are becoming game changer in the pharmaceutical industry by providing deeper information on drug localization and its efficacy. These innovative capabilities are also combined with powerful proprietary image analysis to help our clients evaluate targeted biomarkers for preclinical and clinical samples and classify patients based on tissue biomarkers.

"We are really pleased to pursue cutting-edge technology that can positively affect patient lives and our Imaging Mass Cytometry capability is a reflection of our dedication to service excellence", said Jonathan Stauber, CEO and Founder of ImaBiotech. "ImaBiotech unique experience and outstanding capabilities help ensure the successful execution of clinical patient sample analysis", he added.

About ImaBiotech

ImaBiotech is a unique innovative bioanalytical service company to support new drug development programs. ImaBiotech combines standards bioanalytical methods with advanced mass spectrometry imaging and spatial biology (histology, multi-omics, spatialomics) techniques in order to decipher the complexity of drug activities. The combination of unique capabilities with advanced digital pathology tools makes possible the measurement of drug activity and drug response, simultaneously, at the single cell level. This performance enables comprehensive drug efficacy evaluation from preclinical to clinical stages. Founded in 2010, based in Lille, France, with a subsidiary in the US, ImaBiotech has received an award for the most innovative start-up company in France with 47 patents applied worldwide by Forbes and Patent-angels.com.

Imabiotech – Next Generation Imaging Services (<https://www.imabiotech.com/>)

Contact

Corinne Ramos

ramos.corinne@imabiotech.com

+33 (0) 374 095 546

--- End ---

Source	ImaBiotech
City/Town	Lille
State/Province	Nord-pas-de-calais
Country	France
Industry	Biotech
Tags	

Link [Drug Development Spatialomics](https://prlog.org/12911825)
<https://prlog.org/12911825>



Scan this QR Code with your SmartPhone to-

- * Read this news online
- * Contact author
- * Bookmark or share online